Compare Quest Diagnostics Inc (DGX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Schlumberger NV — how do they compare? Quest Diagnostics Inc trades at $236.62 (market cap $26.21B), while Schlumberger NV trades at $52.95 (market cap $79.67B). The key difference: Schlumberger NV is far larger — about 3× Quest Diagnostics Inc's market cap, and Schlumberger NV pays the higher dividend (2.2%). Which is the better fit depends on your goals.
| DGX | SLB | |
|---|---|---|
Market Cap | $26.21B | $79.67B |
Sector | Health | Energy |
52-Week High | $238.50 | $58.01 |
52-Week Low | $173.49 | $31.72 |
Enterprise Value | $31.97B | $88.40B |
Dividend Yield | 1.45% | 2.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
SLB trades at $53.20, up 5.28% over the past day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.55 versus $0.511 expected, driven by digital and production growth. Revenue for 2025 was $35.71 billion, with net income of $3.37 billion, though margins have compressed from prior years. The stock shows robust institutional support and positive media sentiment following upbeat results.
Outlook remains positive with a consensus price target of $63.00, implying 18% upside, supported by offshore and digital expansion. Risks include Middle East volatility and net debt concerns. The dividend yield is modest at around 1.1%, with the next payment scheduled for October 2026. Investors should weigh growth catalysts against regional and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
